Although Her2 targeted therapy, in particular monoclonal antibodies alone or in combination with chemotherapy, was confirmed to have favorable effects on breast cancer treatment and had improving impacts on prognosis [13], the results of anti-Her2 therapy in NSCLC were conflicting. This evidence concerns the gene ERBB2 and breast carcinoma.